(Q37684221)

22 August 2017

1 reference

title

Recent advances in improving the management of sickle cell disease (English)

1 reference

22 August 2017

0 references

Adlette Inati

1

1 reference

22 August 2017

publication date

1 December 2009

1 reference

22 August 2017

1 reference

22 August 2017

volume

23 Suppl 1

1 reference

22 August 2017

page(s)

S9-13

1 reference

Sickle cell disease: new insights into pathophysiology and treatment.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Indications for red cell transfusion in sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Circumstances of death in adult sickle cell disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

The importance of non-transferrin bound iron in disorders of iron metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

Oral iron chelation and the treatment of iron overload in a pediatric hematology center

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2809%2970004-9

7 January 2021

10.1016/S0268-960X(09)70004-9

Identifiers

DOI

1 reference

22 August 2017

1 reference